{"url":"https://newsforagent.com/news/2026-10-24/zomedica-clinical-program-webinar","markdown_url":"https://newsforagent.com/news/2026-10-24/zomedica-clinical-program-webinar.md","title":"Zomedica Presents Clinical Data Across Three Product Lines","headline":"Zomedica Webinar Details Studies for PulseVet, VETGuardian PLUS and TRUFORMA","description":"Zomedica presented clinical studies across three product lines on October 23, 2026, aiming to show veterinarians how evidence drives adoption of its devices.","section":"Research & Clinical Trials","published_at":"2026-10-24T05:20:47+00:00","modified_at":"2026-10-24T05:20:47+00:00","author":"News Desk","key_takeaways":["Zomedica presented clinical studies across the PulseVet Shock Wave system, the VETGuardian PLUS monitor and the TRUFORMA immunoassay platform on October 23, 2026.","Zomedica reported record second quarter 2026 revenue of $9.5 million, up 37% year-over-year.","Zomedica's 2025 full year revenue was $32.0 million, representing 17% annual growth."],"companies":[{"name":"Zomedica","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000ho2/zomedica","website":"http://www.zomedica.com"}],"source":{"publisher":"Seeking Alpha","title":"Zomedica Corp. (ZOMDF) Discusses Clinical Program and Evidence-Driven Adoption in Veterinary Products Transcript","url":"https://seekingalpha.com/article/4957114-zomedica-corp-zomdf-discusses-clinical-program-and-evidence-driven-adoption-in-veterinary?source=feed_all_articles"},"other_sources":[],"tags":["Research & Clinical Trials","Zomedica"],"body_markdown":"[Zomedica](https://akta.pro/company-profiles/0000ho2/zomedica) Corp. presented its clinical program and evidence-driven adoption strategy in an investor webinar on October 23, 2026, covering studies across three product lines: the PulseVet Shock Wave system, the VETGuardian PLUS monitor and the TRUFORMA immunoassay platform. [Seeking Alpha](https://seekingalpha.com/article/4957114-zomedica-corp-zomdf-discusses-clinical-program-and-evidence-driven-adoption-in-veterinary?source=feed_all_articles) published a transcript of the session. Zomedica is a publicly traded animal health company that develops and sells diagnostic platforms and therapeutic devices to companion animal and equine veterinarians across the US, Canada and the EU.\n\n## What Zomedica's Clinical Webinar Covered\n\nThe webinar, part of Zomedica's Fourth Friday at Four series, featured company veterinarians discussing studies across the three product lines. For each study, the presentation asked the same two questions: what the study showed and what it changes commercially. \"Veterinarians buy on evidence,\" the company said during the session, adding that in veterinary medicine products sometimes reach the clinic without any published data behind them. Zomedica said it builds that evidence into every product line. The presentation also included a brief look at the company's mission and the framework anchoring its work. Larry Heaton, Zomedica's president, chief executive officer and director, was listed among the company participants, along with Ashley Wood, T. J. Barclay, Roderick Richards, Kelli Puccio, Kristin Marzin, Kim Keeton and Tanja Buchmann.\n\n## Zomedica's Revenue and Partnership Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Zomedica reported $32.0 million in full year 2025 revenue, representing 17% annual growth and marking its 20th consecutive quarter of record year-over-year revenue. The company reported record first quarter 2026 revenue of $8.8 million, a 35% increase year-over-year and its 21st consecutive quarter of record revenue growth. In March 2026, Zomedica entered a strategic collaboration with Boehringer Ingelheim Animal Health to integrate TRUFORMA into Boehringer's PPID awareness and testing program for horses, with Boehringer reimbursing veterinarians and providing no-cost analyzer placements.\n\n## Zomedica's Recent Webinar Series\n\nZomedica hosted an investor webinar on September 25, 2026, detailing its marketing organization's demand-creation process, with a strategy focused on three phases: land, deepen and expand, supporting two distinct product portfolios, Seeking Alpha reported. On July 24, 2026, the company held an investor webinar to discuss its sales strategy and execution framework for veterinary diagnostic and therapeutic technologies, also per Seeking Alpha. Zomedica announced a webinar scheduled for August 28, 2026, to showcase its international expansion strategy, including distributor infrastructure and global market opportunities, Stock Titan reported.\n\n## Zomedica's Next Webinar\n\nZomedica's Fourth Friday at Four series continued with the October 23, 2026 clinical program session. The company announced the August 28, 2026 webinar on international expansion in August 2026.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}